Skip to main content
Clinical Trials/NCT00987090
NCT00987090
Unknown
Not Applicable

Early-onset and Late-onset Sporadic Alzheimer's Disease (AD) : Variations of the Clinical Profile and Paraclinical Features Depending on the Age at the Onset of Clinical Signs

Assistance Publique Hopitaux De Marseille1 site in 1 country240 target enrollmentOctober 2009

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Alzheimer's Disease
Sponsor
Assistance Publique Hopitaux De Marseille
Enrollment
240
Locations
1
Primary Endpoint
to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.
Last Updated
10 years ago

Overview

Brief Summary

Alzheimer's disease (AD) is usually associated with aging, age being the principal identified risk factor. However, younger subjects also develop AD and the prevalence of early onset AD is unknown. It is estimated that about 30 000 subjects develop symptoms of AD before the age of 65 in France. There is evidence that early onset AD differs from AD in older patients. In particular, clinical and neuroimaging studies suggest early involvement of neocortical brain regions and their functions in early onset AD, while mediotemporal areas and memory might be more involved in late onset AD. These differences could partly explain the atypical clinical and imaging features of younger patients, the diagnostic difficulties in these patients and the specific problems related to medical care of this age group. The present study uses a multidisciplinary approach with longitudinal followup in order to establish the impact of age on the clinical and neuroimaging picture of sporadic AD in a multicentric setting. Another aim of the project is to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.

Registry
clinicaltrials.gov
Start Date
October 2009
End Date
September 2016
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Arm Alzheimer Disease : first symptoms from 1 to 5 years before the inclusion, Clinical Dementia Rating = 1, efficient contraception for women
  • Arm Control : efficient contraception for women

Exclusion Criteria

  • Important general disease : diabetes, neoplasia, alcoholism
  • First symptoms less than 1 year or more than 5 years before the inclusion
  • Pregnancy, breast feeding

Outcomes

Primary Outcomes

to establish the impact of age on the clinical and neuroimaging picture of sporadic Alzheimer Disease in a multicentric setting.

Time Frame: 3 years

Secondary Outcomes

  • to describe for each age group, and in particular for the younger patient group, the functional impact of disability in everyday life on both, patients and caregivers.(3 years)

Study Sites (1)

Loading locations...

Similar Trials